Evidence map›Paper›PMID 35184927›Full record

ArticleVaccine2022

WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.

Erin Sparrow, Ifedayo Adetifa, Nathorn Chaiyakunapruk, Thomas Cherian, Deshayne B Fell, Barney S Graham, Bruce Innis, David C Kaslow, Ruth A Karron, Harish Nair and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Acute rheumatic fever and rheumatic heart disease.Nature reviews. Disease primers · 2026
    Review
  5. Article
  6. Review
  7. Observational
  8. Observational
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Observational
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 8 countries.

Erin SparrowWorld Health Organization, Switzerland; School of Public Health and Community Medicine, UNSW Sydney, Australia. Electronic address: sparrowe@who.int.
Ifedayo AdetifaKEMRI-Wellcome Trust Research Programme, Kenya; London School of Hygiene & Tropical Medicine, UK.
Nathorn ChaiyakunaprukCollege of Pharmacy, The University of Utah, USA.
Thomas CherianMMGH Consulting GmbH, Switzerland.
Deshayne B FellSchool of Epidemiology & Public Health, University of Ottawa, Canada; Children's Hospital of Eastern Ontario Research Institute, Canada.
Barney S GrahamVaccine Research Center, NIH, USA.
Bruce InnisPATH, USA.
David C KaslowPATH, USA.
Ruth A KarronJohns Hopkins Bloomberg School of Public Health, USA.
Harish NairCentre for Global Health, Usher Institute, Edinburgh Medical School, University of Edinburgh, UK.
Kathleen M NeuzilUniversity of Maryland School of Medicine, USA.
Samir SahaChild Health Research Foundation and Bangladesh Institute of Child Health, Bangladesh.
Peter G SmithLondon School of Hygiene & Tropical Medicine, UK.
Padmini SrikantiahBill & Melinda Gates Foundation, Seattle, USA.
Fred WereSchool of Medicine, University of Nairobi, Kenya.
Heather J ZarDepartment of Paediatrics and Child Health, and SA-MRC unit on Child and Adolescent Health, University of Cape Town, South Africa.
Daniel FeikinWorld Health Organization, Switzerland.
Program for Appropriate Technology in Health · USWorld Health Organization · CHBill & Melinda Gates Foundation · USChild Health Research Foundation · BDJohns Hopkins University · USKenya Medical Research Institute · KELondon School of Hygiene & Tropical Medicine · GBSouth African Medical Research Council · ZAUniversity of Edinburgh · GBUniversity of Maryland, Baltimore · USUniversity of Nairobi · KEUniversity of Ottawa · CAUniversity of Utah · US

Funding

Medical Research Council MR/R010161/1World Health Organization 001
6 · The paper itself

Abstract

World Health Organization (WHO) preferred product characteristics describe preferences for product attributes that would help optimize value and use to address global public health needs, with a particular focus on low- and middle-income countries. Having previously published preferred product characteristics for both maternal and paediatric respiratory syncytial virus (RSV) vaccines, WHO recently published preferred product characteristics for monoclonal antibodies to prevent severe RSV disease in infants. This article summarizes the key attributes from the preferred product characteristics and discusses key considerations for future access and use of preventive RSV monoclonal antibodies.

Indexed as

Communicable DiseasesRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAntibodies, MonoclonalAntibodies, ViralChildHumansImmunization, PassiveInfantWorld Health OrganizationAntibodies, MonoclonalAntibodies, ViralRespiratory Syncytial Virus VaccinesMonoclonal antibodyPassive immunizationRespiratory syncytial virus

Identifiers

PMID35184927
PMCPMC9176315
OpenAlexW4213117536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.